Regenacy Pharmaceuticals
Todd Kaloudis is a co-founder and general partner of two biotech venture capital funds managed by Cobro Ventures. He currently serves on the board of directors at Regenacy Pharmaceuticals, Techsomed, AI Proteins, Dynamic Cell Therapies, and Mana Therapeutics. Todd contributed to the early growth of two Cobro-backed biotech ventures: C4 Therapeutics (IPO 2020), and Frequency Therapeutics (IPO 2019). He served in global C-suite operating roles at technology companies Dynatrace ($2.4B acquisition by Thoma Bravo 2014) and OPNET Technologies (IPO 2000, $1B acquisition by Riverbed Technology 2012), and as an advisor to Platform Science ($115M financing led by Softbank 2022). Todd studied computer science at MIT as an undergraduate, where he was admitted to the Eta Kappa Nu academic honors society.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Regenacy Pharmaceuticals
Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.